2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boostOutcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed?
Shah N, Ngwube A, Jacobsohn D, Shenoy S. Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed? Blood 2023, 142: 2185. DOI: 10.1182/blood-2023-190524.Peer-Reviewed Original ResearchDisease-free survivalSickle cell diseaseSevere sickle cell diseaseUnrelated donor transplantsGVHD prophylaxisAllogeneic transplantationCell diseaseChronic GVHDDonor transplantsMarrow transplantationGrade 2Unrelated donor stem cell transplantationAllogeneic T cell proliferationDonor stem cell transplantationUnrelated donor marrow transplantationCalcineurin inhibitor useHost disease (GVHD) prophylaxisRelated donor transplantsSevere chronic GVHDSuccessful allogeneic transplantationGroup 1 patientsPhase II trialImmune suppression therapyStem cell transplantationHuman leucocyte antigenRole of abatacept in the prevention of graft-versus-host disease: current perspectives
Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMID: 36845849, PMCID: PMC9943961, DOI: 10.1177/20406207231152644.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantChronic GVHDGVHD prophylaxisDonor hematopoietic stem cell transplantSteroid-refractory chronic GVHDPrevention of graftSevere acute GVHDStem cell transplantAcute GVHDGVHD preventionHLA disparityHost diseaseGraft rejectionHSCT settingUnrelated donorsCalcineurin inhibitorsCell transplantNonmalignant disordersAlternative donorsMouse modelClinical practiceGVHDProphylaxisLimited reports
2021
Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia
Gorfinkel L, Demsky C, Pashankar F, Kupfer G, Shah NC. Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia. Pediatric Transplantation 2021, 25: e14009. PMID: 33755277, DOI: 10.1111/petr.14009.Peer-Reviewed Original ResearchConceptsUnrelated donor transplantsDonor transplantsBM graftsVivo T-cell depletionReduced intensity conditioning regimenStem cell transplant programInclusion of alemtuzumabNon-TBI conditioningPost-transplant complicationsSuccess of HSCTDevelopment of GVHDT-cell depletionIntensity conditioning regimenBone marrow transplantFull immune reconstitutionChronic GVHDCyclophosphamide conditioningGVHD prophylaxisMSD transplantsImmune reconstitutionConditioning regimenLate complicationsConditioning regimensSecondary neoplasmsSecondary malignancies
2019
Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)
Ngwube A, Shah N, Jacobsohn D, Dela Ziga E, Shenoy S. Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD). Blood 2019, 134: 370. DOI: 10.1182/blood-2019-126405.Peer-Reviewed Original ResearchSevere sickle cell diseaseEvent-free survivalHost disease preventionAntigen-presenting cellsSickle cell diseaseURD-SCTLower incidenceAcute GVHDChronic GVHDGVHD prophylaxisAcute graftOverall survivalCell transplantationCell diseaseSevere SCDT cell co-stimulation blockadeUnrelated donor hematopoietic cell transplantationUnrelated donor stem cell transplantationDisease preventionAcute chest syndrome episodesDonor stem cell transplantationUnrelated donor marrow transplantationVaso-occlusive pain crisesAcute GVHD incidenceAcute GVHD preventionGRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances 2019, 3: 1441-1449. PMID: 31053571, PMCID: PMC6517657, DOI: 10.1182/bloodadvances.2018030171.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlemtuzumabBone Marrow CellsChildChild, PreschoolDisease-Free SurvivalFemaleFetal BloodGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaProportional Hazards ModelsRecurrenceSurvival RateThyroglobulinTransplantation ConditioningWhole-Body IrradiationConceptsRelapse-free survivalPediatric patientsGrade IIIBM groupAcute leukemiaHigh riskAlternative donor hematopoietic cell transplantationTotal body irradiation-based conditioningMultivariate analysisDonor hematopoietic cell transplantationFree relapse-free survivalCox proportional hazards modelAnti-thymocyte globulinHematopoietic cell transplantationIrradiation-based conditioningAcute lymphoblastic leukemiaProportional hazards modelUmbilical cord bloodBM recipientsGraft variablesGVHD prophylaxisUCB groupHost diseaseMycophenolate mofetilClinical characteristics